- Cassava Sciences ( NASDAQ: SAVA ) has begun an open-label extension study of its Alzheimer's disease candidate simufilam that will last a year.
- The trial is expected to enroll ~1.6K participants. Enrollment is set to begin in November.
- The study is for participants that have completed one of the company's two phase 3 trials. They will be given 100 mg simufilam twice daily.
- Seeking Alpha contributor Biotech Beast views Cassava Sciences ( SAVA ) as a strong sell as there is still a great deal of uncertainty hanging over the stock .
For further details see:
Cassava Sciences begins extension study of Alzheimer's drug simufilam